Literature DB >> 4031953

Cockayne syndrome: clinicopathologic and tissue culture studies of affected siblings.

R W Leech, R A Brumback, R H Miller, F Otsuka, R E Tarone, J H Robbins.   

Abstract

Two siblings with Cockayne syndrome (CS) had extremely severe and early onset cachectic dwarfism, developmental delay, cataracts, microcephaly, peripheral neuropathy, and spastic quadriplegia. In order to study the inherited DNA-repair defect known to be present in cultured CS cells, a lymphoblastoid line was established from the younger sibling. Tissue culture studies revealed the line to have a hypersensitivity to the lethal effects of 254-nm ultraviolet radiation (UV) equivalent to that of lymphoblastoid lines from CS patients who had either the usual severity or a very mild form of CS. Autopsy of the older sibling at six years of age showed the brain to be severely atrophic, with particularly severe cerebellar atrophy. There was a marked reduction in the number of granule cells in the cerebellum and irregular patchy myelination throughout the brain. Many astrocytes contained either a large, bizarre-shaped nucleus or multiple nuclei. Some Purkinje cells of the cerebellum and pyramidal neurons of the hippocampus were binucleated. It is suggested that the DNA-repair defect of CS causes abnormalities in nuclear DNA replication and cell division which result in cell death and in the observed nuclear abnormalities.

Entities:  

Mesh:

Year:  1985        PMID: 4031953

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  14 in total

1.  Increased apoptosis, p53 up-regulation, and cerebellar neuronal degeneration in repair-deficient Cockayne syndrome mice.

Authors:  R R Laposa; E J Huang; J E Cleaver
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-17       Impact factor: 11.205

2.  Molecular cloning and structural analysis of the functional mouse genomic XPG gene.

Authors:  D L Ludwig; J S Mudgett; M S Park; A V Perez-Castro; M A MacInnes
Journal:  Mamm Genome       Date:  1996-09       Impact factor: 2.957

3.  Neuroimaging in Cockayne syndrome.

Authors:  M Koob; V Laugel; M Durand; H Fothergill; C Dalloz; F Sauvanaud; H Dollfus; I J Namer; J-L Dietemann
Journal:  AJNR Am J Neuroradiol       Date:  2010-06-03       Impact factor: 3.825

Review 4.  Cockayne syndrome: Clinical features, model systems and pathways.

Authors:  Ajoy C Karikkineth; Morten Scheibye-Knudsen; Elayne Fivenson; Deborah L Croteau; Vilhelm A Bohr
Journal:  Ageing Res Rev       Date:  2016-08-06       Impact factor: 10.895

5.  Nephrotic syndrome, hypertension, and adrenal failure in atypical Cockayne syndrome.

Authors:  U Reiss; K Hofweber; R Herterich; R Waldherr; E Bohnert; E Jung; K Schärer
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

6.  Cockayne syndrome: a diffusion tensor imaging and volumetric study.

Authors:  Mériam Koob; François Rousseau; Vincent Laugel; Nicolas Meyer; Jean-Paul Armspach; Nadine Girard; Jean-Louis Dietemann
Journal:  Br J Radiol       Date:  2016-09-19       Impact factor: 3.039

Review 7.  The case for 8,5'-cyclopurine-2'-deoxynucleosides as endogenous DNA lesions that cause neurodegeneration in xeroderma pigmentosum.

Authors:  P J Brooks
Journal:  Neuroscience       Date:  2006-12-19       Impact factor: 3.590

Review 8.  Cockayne syndrome and xeroderma pigmentosum.

Authors:  I Rapin; Y Lindenbaum; D W Dickson; K H Kraemer; J H Robbins
Journal:  Neurology       Date:  2000-11-28       Impact factor: 9.910

9.  Mental retardation syndrome with renal concentration deficiency and intracerebral calcification.

Authors:  O Schofer; R Beetz; J Bohl; A Bornemann; J Oepen; J Spranger
Journal:  Eur J Pediatr       Date:  1990-04       Impact factor: 3.183

10.  Clinical implications of the basic defects in Cockayne syndrome and xeroderma pigmentosum and the DNA lesions responsible for cancer, neurodegeneration and aging.

Authors:  J E Cleaver; I Revet
Journal:  Mech Ageing Dev       Date:  2008-02-03       Impact factor: 5.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.